Vanda Pharmaceuticals Receives Strong Buy Rating Amidst Growth in Key Product Lines and Promising FDA Decision on Bysanti

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Vanda Pharmaceuticals with a $20.00 price target. Vanda's strong performance and growth potential in key product lines, including Fanapt prescriptions and sales, as well as its direct-to-consumer campaign and resilient HETLIOZ franchise, support the rating. The upcoming FDA decision on Bysanti also presents a promising opportunity for the company.